Insider Transactions in Q1 2024 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
913
-3.8%
|
$383,460
$420.24 P/Share
|
|
Feb 12
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,145
-6.2%
|
$1,320,900
$420.24 P/Share
|
|
Feb 12
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,374
-12.43%
|
$577,080
$420.24 P/Share
|
|
Feb 09
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,100
-2.97%
|
$886,200
$422.74 P/Share
|
|
Feb 09
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,607
-3.95%
|
$1,100,154
$422.74 P/Share
|
|
Feb 09
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,022
-2.54%
|
$853,284
$422.74 P/Share
|
|
Feb 09
2024
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,255
-4.84%
|
$3,483,610
$422.74 P/Share
|
|
Feb 09
2024
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,100
-4.29%
|
$886,200
$422.74 P/Share
|
|
Feb 09
2024
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,588
-7.35%
|
$670,136
$422.74 P/Share
|
|
Feb 09
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,177
-3.82%
|
$1,340,694
$422.74 P/Share
|
|
Feb 09
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
832
-3.34%
|
$351,104
$422.74 P/Share
|
|
Feb 09
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,099
-3.97%
|
$885,778
$422.74 P/Share
|
|
Feb 09
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
591
-5.08%
|
$249,402
$422.74 P/Share
|
|
Feb 09
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
8,048
-20.99%
|
$3,396,256
$422.74 P/Share
|
|
Feb 08
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,698
-6.57%
|
$1,135,858
$421.73 P/Share
|
|
Feb 07
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+9.15%
|
-
|
|
Feb 07
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+9.72%
|
-
|
|
Feb 07
2024
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
7,707
+15.81%
|
-
|
|
Feb 07
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+8.2%
|
-
|
|
Feb 07
2024
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
20,327
+10.65%
|
-
|
|
Feb 07
2024
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,928
+10.81%
|
-
|
|
Feb 07
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
4,743
+16.01%
|
-
|
|
Feb 07
2024
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,743
+18.0%
|
-
|
|
Feb 07
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,853
+13.73%
|
-
|
|
Feb 07
2024
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
8,448
+9.22%
|
-
|
|
Feb 07
2024
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,114
+11.87%
|
-
|
|
Feb 06
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
14,842
+11.09%
|
-
|
|
Feb 06
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,254
+12.16%
|
-
|
|
Feb 06
2024
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
30,916
+41.42%
|
-
|
|
Feb 06
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
13,680
+9.02%
|
-
|
|
Feb 06
2024
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
41,488
+12.88%
|
-
|
|
Feb 06
2024
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
13,680
+14.84%
|
-
|
|
Feb 06
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
6,260
+14.45%
|
-
|
|
Feb 06
2024
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,294
+27.18%
|
-
|
|
Feb 06
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,950
+23.16%
|
-
|
|
Feb 06
2024
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
18,186
+11.47%
|
-
|
|
Feb 06
2024
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,680
+14.0%
|
-
|
|
Jan 08
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
6,648
-73.29%
|
$2,785,512
$419.07 P/Share
|
|
Jan 02
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.42%
|
$1,215,000
$405.0 P/Share
|